SCHEMBL20747744

SCHEMBL20747744

C[C@@H](OC(=O)C(C)(C)N)C(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GRM1 Q13255 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18067543 1.00 GRM1 (0.33) GRM1
SCHEMBL20747594 0.81
SCHEMBL18067491 0.81
SCHEMBL15702222 0.80 PRKCA (0.42) GRM1
SCHEMBL4678096 0.80 TSHR (0.43)
SCHEMBL20747717 0.79
Hydrochloric Acid SCHEMBL4276809 0.78 TSHR (0.42)
SCHEMBL5665771 0.75 LMNA (0.41) GRM1
SCHEMBL16987582 0.75 LMNA (0.41) GRM1
SCHEMBL19500214 0.75 LMNA (0.41) GRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10208045-B2 Aza-pyridone compounds and uses thereof ALIOS BIOPHARMA, INC. (US) 2019-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10208045-B2 Aza-pyridone compounds and uses thereof PNPO, ITPA, PDXK GRM1 2107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.